Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios

Ting Yung Chang, Jo Nan Liao, Tze Fan Chao*, Jennifer Jeanne Vicera, Chin Yu Lin, Ta Chuan Tuan, Yenn Jiang Lin, Shih Lin Chang, Li Wei Lo, Yu Feng Hu, Fa Po Chung, Shih Ann Chen

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

33 Scopus citations

Abstract

Atrial fibrillation (AF) has become the most prevalent arrhythmia and it will increase the risk of ischemic stroke, heart failure, mortality, sudden cardiac death, myocardial infarction, and dementia. Stroke prevention with oral anticoagulant is crucial for management of AF patients. Vitamin K antagonist, which inhibits the clotting factors II, VII, IX and X, has been recommended for stroke prevention for decades. Non-Vitamin K antagonist oral anticoagulants (NOACs), including dabigatran, rivaroxaban, apixaban and edoxaban are at least as effective as warfarin in reducing ischemic stroke with a lower rate of major bleeding. With the increasing prevalence of AF, prescription of the appropriate oral anticoagulants (OACs) according to patient's characteristics becomes a challenge. This review article aims to provide an overview of anticoagulant use in AF patients with difficult scenarios.

Original languageEnglish
Pages (from-to)56-62
Number of pages7
JournalIJC Heart and Vasculature
Volume20
DOIs
StatePublished - Sep 2018

Keywords

  • Atrial fibrillation
  • Chronic kidney disease
  • Coronary intervention
  • Oral anticoagulation
  • Valvular heart disease

Fingerprint

Dive into the research topics of 'Oral anticoagulant use for stroke prevention in atrial fibrillation patients with difficult scenarios'. Together they form a unique fingerprint.

Cite this